Songjiang Ma Sells 1,057 Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) President Songjiang Ma sold 1,057 shares of the stock in a transaction on Friday, January 10th. The shares were sold at an average price of $10.02, for a total value of $10,591.14. Following the transaction, the president now directly owns 2,915,194 shares in the company, valued at $29,210,243.88. The trade was a 0.04 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Songjiang Ma also recently made the following trade(s):

• On Monday, January 13th, Songjiang Ma sold 56 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.10, for a total value of $565.60.
• On Monday, January 6th, Songjiang Ma sold 941 shares of Gyre Therapeutics stock. The shares were sold at an average price of $10.16, for a total value of $9,560.56.
• On Thursday, January 2nd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.40, for a total value of $24,800.00.
• On Monday, December 30th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.50, for a total value of $25,000.00.
• On Thursday, December 26th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.70, for a total value of $25,400.00.
• On Monday, December 23rd, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $12.27, for a total value of $24,540.00.
• On Thursday, December 19th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $10.82, for a total value of $21,640.00.
• On Tuesday, December 17th, Songjiang Ma sold 2,000 shares of Gyre Therapeutics stock. The stock was sold at an average price of $11.05, for a total value of $22,100.00.

Gyre Therapeutics Trading Up 5.3 %

Shares of NASDAQ:GYRE traded up $0.53 during midday trading on Tuesday, hitting $10.52. The company had a trading volume of 105,910 shares, compared to its average volume of 156,989. Gyre Therapeutics, Inc. has a 12-month low of $8.26 and a 12-month high of $26.37. The company has a fifty day moving average of $11.83 and a two-hundred day moving average of $12.66.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of GYRE. FMR LLC purchased a new stake in Gyre Therapeutics in the 3rd quarter worth $47,000. Barclays PLC increased its stake in Gyre Therapeutics by 281.8% in the 3rd quarter. Barclays PLC now owns 9,288 shares of the company's stock worth $116,000 after buying an additional 6,855 shares in the last quarter. Rhumbline Advisers purchased a new stake in Gyre Therapeutics in the 2nd quarter worth $123,000. Renaissance Technologies LLC purchased a new stake in Gyre Therapeutics in the 2nd quarter worth $166,000. Finally, Bank of New York Mellon Corp purchased a new stake in Gyre Therapeutics in the 2nd quarter worth $218,000. 23.99% of the stock is currently owned by hedge funds and other institutional investors.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.